Chongqing basic drug supplement quietly gives priority to local enterprises
-
Last Update: 2013-08-01
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On Wednesday, the reporter received internal news that the local supplement work of Chongqing Health Bureau is quietly going on, and some local enterprises have received the fax of the notice In response, the head of the office of the local health bureau said, "we do not give priority to local enterprises, all enterprises can declare", but no official documents were found on the official website of the Municipal Health Bureau On August 31, Chongqing Municipal Bureau of Health issued the notice of Chongqing Municipal Bureau of health on the requirements of applying for access to the list of supplementary essential drugs in Chongqing The notice pointed out that as of August 6, 2013, enterprises had applied to the Health Bureau for varieties to adjust and improve the list of essential drugs in Chongqing, and stressed that the number of supplementary directories was limited It may be a special protection for local enterprises due to the urgency of time, limited quota and fax The aforementioned person said that although the number of supplements is limited according to the documents, the number of supplements should also be determined according to the application of enterprises and the clinical medication situation "When each enterprise applies, it should limit to one or two varieties as far as possible", and local enterprises will not be given priority In the view of the industry, it is an indisputable fact to give priority to local enterprises "It's the same in all provinces of China now, because the quota is really limited, enterprises in the province are given priority," said a person familiar with the matter In addition, Chongqing Health Bureau said that the supplement catalogue will be published in about 2-3 months, and this supplement will limit the application of exclusive varieties, "because the price of exclusive varieties can not be reduced in the bidding, and it is not necessarily necessary for clinical use.".
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.